ArticleAdvances in radiation oncology2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung Cancer.
Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Stereotactic ablative radiation therapy (SABR) is a standard of care for early-stage lung cancer and thoracic oligometastatic or oligoprogressive disease. However, ultracentral lesions remain challenging because of their proximity to critical mediastinal structures and the associated risk of severe toxicity. Stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) allows for daily plan adaptation and real-time tracking in breath-hold, enhancing target coverage while improving sparing of adjacent organs compared to conventional SABR. Methods and Materials: This retrospective study analyzed outcomes of SMART-based SABR for ultracentral metastatic lesions in patients with histologically confirmed non-small cell lung cancer (NSCLC). Ultracentral lesions were defined by planning target volume overlapping with the proximal bronchial tree, esophagus, or pulmonary vessels. Endpoints included grade ≥ 3 SMART-related toxicity, freedom from local progression, progression-free survival, and overall survival. Results: Between 2020 and 2023, 11 patients with 18 ultracentral NSCLC lesions underwent SMART. All treatments were delivered in breath-hold. The median dose was 40 Gy (range, 30-60 Gy) in 5 to 8 fractions. Online plan adaptation was performed for 100% of the 78 delivered fractions. No grade ≥ 3 toxicities were observed. Rates of grade 1 to 2 acute and late toxicities were 54% and 18%, respectively. At a median follow-up of 28 months (range, 5-41 months), 66.7% of patients were alive. One-year freedom from local progression was 93%. Median progression-free survival was 5.8 months (range, 1-39 months), and median overall survival was 20 months (range, 5-41 months). Conclusions: SMART with daily online adaptation achieved excellent local control and a favorable safety profile in ultracentral NSCLC, comparable to conventional non-adaptive SABR, but without severe toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.